Results for tumor necrosis factor translation from English to Maltese

tumor necrosis factor alpha (tnf- α) inhibitors.
inibituri tal- fattur tan- nekrosi tat- tumur (tnf- α).

pharmacotherapeutic group: immunosuppressants, tumor necrosis factor alpha (tnf-α) inhibitors,atc code: l04ab01
kategorija farmakoterapewtika: immunosoppressanti, inibituri alpha tal-fattur tan-nekrosi tat-tumur (tnf-α), kodiċi atc: l04ab01

beromun contains the active substance tasonermin (tumor necrosis factor alfa-1a), produced by recombinant dna technology.
beromun fih is-sustanza attiva tasonermin (fattur tan-nekrosi tat-tumur alfa-1a), magħmula minn teknoloġija tad-dna rikombinanti.

cimzia binds to a specific protein called tumour necrosis factor α (tnfα).
cimzia jeħel ma’ proteina speċifika li jismimha fattur tan-nekrożi tat-tumur α (tnf-α).

tumour necrosis factor alpha (tnfα) mediates inflammation and modulates cellular immune responses.
fattur alfa tan-necrożi tat-tumur (tnfα) jikkontrolla l-infjammazzjoni u jimmodula ir-rispons immuni taċ-ċelluli.

pharmacotherapeutic group: immunosuppressants, tumour necrosis factor alpha (tnf-α) inhibitors.
kategorija farmakoterapewtika: immunosuppressanti , inibitturi ta’ tumur nekrosi fattur alfa (tnf- α).

medicines called tumour necrosis factor (tnf) inhibitors, such as etanercept, adalimumab or infliximab.
mediċini magħrufa bħala inibituri tal-fattur tan-nekrosi tat-tumur (tnf), bħalma huma etanercept, adalimumab jew infliximab.

adalimumab has been designed to bind to a chemical messenger in the body called tumour necrosis factor (tnf).
adalimumab ġie ddisinjat biex jeħel ma’ messaġġier kimiku fil-ġisem

pharmacotherapeutic group: immunosuppressants, tumour necrosis factor alpha (tnfα) inhibitors, atc code: l04ab02.
kategorija farmakoterapewtika: immunosoppressanti, inibituri tal-fattur tan-necrożi alfa (tnfα), kodiċi atc: l04ab02.

flixabi works by blocking the action of a protein called ‘tumour necrosis factor alpha’ (tnfα).
flixabi jaħdem billi jimblokka l-ħidma ta’ proteina li tissejjaħ ‘fattur tan-nekrożi tat-tumur alfa’ (tnfα).

the active substance in beromun, tasonermin, is a copy of the human protein tumour necrosis factor alfa-1a (tnfα).
is-sustanza attiva f’beromun, tasonermin, hija kopja tal-proteina umana magħrufa bħala l-fattur tan- nekrożi tat-tumur alfa-1a (tnfα).

the use of kineret with tumour necrosis factor (tnf) antagonists (other medicines used in rheumatoid arthritis) is not recommended.
l- użu ta 'kineret ma' antagonisti tal- fattur ta 'nekrożi tumorali (tnf) (mediċini oħrajn użati f' artrite rewmatojde) mhuwiex rakkomandat.

humira belongs to a group of medicines that block the activity of tumour necrosis factor (tnf) in the body (tnf blockers).
humira jappartjeni fi grupp ta’ mediċini li jimblokkaw l-attività ta’ fattur tan-nekrosi tat-tumur (tnf) fil-ġisem (imblokkaturi tat- tnf).

topical in vivo application of imiquimod cream on mouse skin resulted in increased concentrations of ifn and tumour necrosis factor (tnf) compared with skin of untreated mice.
applikazzjoni topika in vivo ta’ krema imiquimod fuq il-ġilda ta’ ġrieden wasslet għal żjieda fil-konċentrazzjonijiet ta’ ifn u tal-fattur tan-nekrosi tat-tumur (tnf) meta mqabbel ma’ ġilda ta’ ġrieden mhux ikkurati.

etanercept is a human tumour necrosis factor receptor p75 fc fusion protein produced by recombinant dna technology in a chinese hamster ovary (cho) mammalian expression system.
etanercept hu proteina umana b’fattur nekrotiku għat-tumuri b’funzjoni tar-riċettur p75 fc, prodott b’teknoloġija rikombinanti tad-dna bis-sistema ta’ espressjoni mammifera fl-ovarji ta’ ħamster Ċiniż (cho).

medicines called tumour necrosis factor (tnf) inhibitors (such as etanercept, adalimumab, or infliximab) predominantly used in rheumatoid and autoimmune disease.
mediċini li jissejħu impedituri tal-fattur tan-nekrosi tat-tumur (bħal etanercept, adalimumab, jew infliximab) li jintużaw prinċipalment għal mard awtoimmuni jew rewmatiku.

the active substance in enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (tnf).
is- sustanza attiva f' enbrel, etanercept, hi proteina li ġiet iddisinjata biex timblokka l- attività ta 'messaġġier kimiku fil- ġisem magħruf bħala fattur tan- nekrożi tat- tumur (tumour necrosis factor - tnf).

adalimumab binds to a specific protein (tumour necrosis factor or tnf), which is present at increased levels in inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
adalimumab jeħel ma’ proteina speċifika (fattur tan-nekrosi tat-tumur jew tnfα), li tinsab f’livelli aktar għolja f’mard infjammatorju bħal artrite rewmatika, artrite psorjatika u infjammazzjoni tal-vertebri li jirriżulta fil-vertebri jitwaħħlu flimkien (ankylosing spondylitis).

upon in vitro stimulation of human neutrophils, monocytes, macrophages or lymphocytes, roflumilast and roflumilast n-oxide suppress the release of inflammatory mediators e.g. leukotriene b4, reactive oxygen species, tumor necrosis factor α, interferon γ and granzyme b.
meta saret stimulazzjoni in vitro ta’ newtrofili, monoċiti, makrofaġi jew limfoċiti umani, roflumilast u roflumilast n-oxide rażżnu l-ħruġ ta’ medjaturi infjammatorji, eż. leukotriene b4, speċi ta’ ossiġnu reattiv, fattur tan-nekrosi tat-tumur α, interferon γ u granzyme b.

certolizumab pegol is a recombinant, humanised antibody fab' fragment against tumour necrosis factor alpha (tnfα) expressed in escherichia coli and conjugated to polyethylene glycol (peg).
certolizumab pegol huwa framment fab' ta’ antikorp umanizzat u rikombinat kontra tumour necrosis factor alpha (tnfα) espress f’ escherichia coli, u wara jiġi purifikat u msieħeb ma’ polyethylene glycol (peg).